Stock 9688 ZAI LAB LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Zai Lab Limited Hong Kong S.E.

Equities

9688

KYG9887T1168

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:05 2024-05-31 am EDT 		5-day change 1st Jan Change
14.64 HKD +6.09% Intraday chart for Zai Lab Limited +3.39% -31.91%
May. 24 Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower MT
May. 22 Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
BU
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
AQ
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China
BU
Zai Lab Announces Participation in May and June Investor Conferences
BU
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
BU
Zai Lab Announces Approval of AUGTYRO for Patients with ROS1-positive NSCLC by China's NMPA
AQ
Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA
BU
Zai Lab : Corporate Presentation
PU
Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates
BU
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
BU
Zai Lab Statement on Executive Management Team's Agreement on Share Activities
AQ
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
BU
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI Meets Primary Endpoint
AQ
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs
BU
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
BU
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases
AQ
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
BU
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors
BU
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)
BU
Zai Lab Announces Participation in March Investor Conference
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ZLAB Stock
  4. 9688 Stock
  5. News Zai Lab Limited
  6. Press Releases